Bulk Pharmaceutical API Sources for MIGLITOL

Bulk Pharmaceutical API Sources for MIGLITOL

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A837526
AKos Consulting & Solutions		AKOS015969689
TCI (Tokyo Chemical Industry)		M2302
Mcule		MCULE-2158237443
Key Organics/BIONET		KS-1242
AbaChemScene		CS-2596

Miglitol Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global sourcing landscape for bulk active pharmaceutical ingredient (API) miglitol. It identifies key manufacturers, analyzes patent protections, and assesses regulatory compliance across major markets.

What is Miglitol?

Miglitol is an alpha-glucosidase inhibitor used in the management of type 2 diabetes mellitus. It functions by slowing the digestion of carbohydrates, thereby reducing postprandial hyperglycemia. The molecule's chemical name is (2R,3R,4R,5S)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrol. The primary API market for miglitol is driven by the generic pharmaceutical sector, following patent expiries of originator products.

Who Manufactures Miglitol API?

Global manufacturing of miglitol API is concentrated among a limited number of producers, primarily located in Asia. These manufacturers cater to the demand for generic drug formulations.

Key Miglitol API Manufacturers

• Gland Pharma Limited (India): A significant player in API manufacturing, Gland Pharma produces miglitol for various markets.
• Intas Pharmaceuticals Ltd. (India): Intas is another established Indian API producer with miglitol in its portfolio.
• Biocon Limited (India): Biocon is a diversified biopharmaceutical company that also engages in API manufacturing, including miglitol.
• Sun Pharmaceutical Industries Ltd. (India): As one of the largest generic pharmaceutical companies globally, Sun Pharma has integrated API manufacturing capabilities, including miglitol.
• Zydus Lifesciences Ltd. (formerly Cadila Healthcare) (India): Zydus Lifesciences is a key supplier of generic APIs, with miglitol among its offerings.
• Eisai Co., Ltd. (Japan): While the originator of miglitol (under the trade name Glyset), Eisai maintains manufacturing capabilities for its own product and potentially for authorized generic production.

Geographic Concentration

The majority of bulk miglitol API manufacturing capacity is situated in India. This concentration is attributable to cost advantages, established pharmaceutical infrastructure, and a large pool of skilled labor. China also has API manufacturers, though specific large-scale miglitol producers are less frequently cited in public domain market analyses compared to Indian entities.

What is the Patent Landscape for Miglitol?

The original patent protection for miglitol has expired in major markets. This has facilitated the entry of generic manufacturers. However, secondary patents related to manufacturing processes, polymorphs, or specific formulations can still exist.

Key Patent Expiries

The foundational patents for miglitol have long since expired. For example, the U.S. patent for miglitol was granted in the late 1980s and early 1990s, with expiration occurring in the mid-2000s. The European patent also expired within a similar timeframe. This has opened the door for widespread generic competition.

Potential Secondary Patents

While the core compound is off-patent, manufacturers may seek to protect novel synthetic routes or crystalline forms.

• Process Patents: Innovations in the chemical synthesis of miglitol, aiming for higher purity, yield, or cost reduction, can be patented. For instance, patents may cover specific catalysts, solvent systems, or purification techniques.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can possess distinct physical properties, such as solubility and bioavailability. Patents on specific, advantageous polymorphs can extend market exclusivity. Research indicates that miglitol can exist in various polymorphic forms [1].
• Formulation Patents: While this report focuses on API, patents on specific drug delivery systems or fixed-dose combinations involving miglitol could impact market dynamics.

Patent Filings Analysis

A review of patent databases (e.g., Google Patents, Espacenet) reveals ongoing filings related to miglitol synthesis and purification. These filings primarily originate from the established API manufacturers and research institutions in India and China, focusing on process optimization rather than novel compound discovery. For example, filings might describe methods to improve the crystallization of miglitol to obtain a specific desired polymorphic form.

What are the Regulatory Requirements for Miglitol API?

Manufacturing and supplying miglitol API requires adherence to stringent regulatory standards established by health authorities in target markets.

Good Manufacturing Practices (GMP)

All manufacturers must comply with current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies. This ensures the quality, safety, and efficacy of the API.

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must meet FDA cGMP guidelines. Facilities are subject to FDA inspection.
• European Medicines Agency (EMA): For the European Union market, compliance with EMA guidelines and national competent authority inspections is mandatory.
• Other Regulatory Bodies: Similar requirements exist for markets such as Japan (PMDA), Canada (Health Canada), and Australia (TGA).

Drug Master Files (DMFs)

API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies. A DMF contains detailed information about the manufacturing process, facility, and quality control of the API.

• U.S. DMF: Submitted to the FDA, this allows drug product manufacturers to reference the API information without disclosing proprietary details.
• ASMF (Active Substance Master File) / CEP (Certificate of Suitability): In Europe, the Active Substance Master File (ASMF) system is used, with Certificates of Suitability (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) being a common alternative that facilitates market access.

Purity and Impurity Profiles

Miglitol API must meet strict purity specifications and have well-characterized impurity profiles. Regulatory bodies set limits for known and unknown impurities.

• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, such as ICH Q3A (R2) for impurities in new drug substances, are universally adopted.
• Specific Impurities: Manufacturers must control process-related impurities and degradation products. Common impurities might include starting materials, intermediates, or isomers.

Quality Control and Testing

Rigorous quality control testing is essential. This includes:

• Assay: Determination of miglitol content.
• Identification: Confirming the identity of the substance (e.g., using IR spectroscopy, HPLC).
• Related Substances: Quantifying and identifying impurities.
• Residual Solvents: Ensuring solvents used in manufacturing are within acceptable limits (ICH Q3C).
• Water Content: Measured by Karl Fischer titration.
• Microbial Limits: Testing for bioburden.

Market Dynamics and Pricing Considerations

The generic nature of miglitol API subjects its market to price sensitivity and competitive pressures.

Supply Chain Stability

The reliance on a few key manufacturers, primarily in India, introduces potential supply chain risks. Geopolitical events, trade disputes, or unexpected plant shutdowns can impact availability and pricing.

Pricing Factors

• Manufacturing Costs: Raw material costs, labor, energy, and regulatory compliance contribute to overall manufacturing expense.
• Competition: The number of API suppliers directly influences price. A larger supplier base typically leads to lower prices.
• Regulatory Hurdles: The cost and time associated with obtaining and maintaining regulatory approvals (e.g., DMF submissions, inspections) add to the overall cost of supply.
• Volume Commitments: Purchasers often negotiate better pricing for larger, consistent volume commitments.

Competitive Landscape for Generic Formulations

The availability of high-quality, competitively priced miglitol API is crucial for generic drug manufacturers. Companies with efficient manufacturing processes and strong regulatory track records have a competitive advantage. The market has seen the introduction of fixed-dose combinations of miglitol with other antidiabetic agents, potentially influencing API demand.

Key Takeaways

• Miglitol API manufacturing is concentrated in India, with key players including Gland Pharma, Intas Pharmaceuticals, Biocon, Sun Pharmaceutical Industries, and Zydus Lifesciences.
• Original patents for miglitol have expired, leading to a competitive generic API market. Secondary patents related to manufacturing processes and polymorphs may still exist.
• Compliance with cGMP, submission of DMFs, and adherence to impurity profile controls are critical for API suppliers across major regulatory jurisdictions (FDA, EMA).
• The market is characterized by price sensitivity due to generic competition, making manufacturing efficiency and regulatory compliance key differentiators for API producers.

Frequently Asked Questions

1. What is the primary regulatory hurdle for new miglitol API manufacturers entering the market? New manufacturers must establish cGMP-compliant facilities and undergo rigorous inspections by regulatory bodies like the FDA and EMA. They also need to prepare and submit comprehensive DMFs or ASMFs, detailing their manufacturing process, quality controls, and impurity profiles, which requires significant investment and expertise.

2. Are there any specific polymorphic forms of miglitol that are preferred by formulators? While specific preferences can vary based on the intended drug product formulation and the originator's patent strategy, formulators generally seek polymorphic forms that offer optimal stability, solubility, and bioavailability. Manufacturers may seek patent protection for advantageous polymorphic forms, influencing their market availability and licensing requirements.

3. What are the typical lead times for sourcing bulk miglitol API from established manufacturers? Lead times can range from 8 to 16 weeks, depending on the supplier's current production schedule, order volume, and the specific quality specifications required. Unexpected demand surges or supply chain disruptions can extend these lead times.

4. Does the presence of fixed-dose combination drugs affect the sourcing strategy for miglitol API? Yes, the development and market approval of fixed-dose combination products that include miglitol can alter API demand patterns. If these combinations become widely adopted, it could lead to increased demand for miglitol API from the manufacturers of these combination products, potentially influencing bulk pricing and supply agreements.

5. How does the impurity profile of miglitol API impact its marketability and price? A well-controlled and well-characterized impurity profile is paramount. API with lower levels of known and unknown impurities, as defined by ICH guidelines and specific pharmacopoeial standards, is generally more desirable and can command a premium price. Manufacturers investing in advanced purification techniques to achieve superior impurity profiles can gain a competitive edge.

Citations

[1] S. K. Singh, S. S. Singh, & J. L. Singh. (2012). Pharmaceutical significance of polymorphs. International Journal of Pharmacy and Pharmaceutical Sciences, 4(3), 28-37.